中西医结合治疗再生障碍性贫血用药选择预测系统的初步研究
|
摘要
目的:研究和评价不同分型再生障碍性贫血(aplastic anemia,AA)患者外周血T细胞亚群、Th1/Th2、T-bet和GATA-3基因表达的变化规律,探讨AA患者不同临床分型、病程以及综合免疫学、分子生物学指标和临床信息等多变量指标的预测系统对AA患者治疗策略选择(免疫抑制剂和雄激素)的预测价值。
方法:采用流式细胞术检测85例AA患者治疗前后外周血T细胞亚群及其他免疫学指标,同时运用实时监测定量PCR技术检测T-bet和GATA-3基因,从中医辨证(肾阳虚/肾阴虚)、西医诊断(急性再障/慢性再障)、疗效(缓解/进步/无效)和治疗方法(雄激素有效/无效和免疫抑制剂有效/无效)四个角度对AA患者进行不同分组,寻找表达显著的免疫学和分子生物学指标,筛选有临床意义并有显著差异性的指标,结合临床诊断依据,以雄激素和免疫抑制治疗有效病例做Logistic回归方程及ROC曲线分析,建立以临床和实验指标为主组成的预测系统,对临床治疗用药选择进行预测。
结果:1.总计85例AA患者经过两个疗程治疗,总有效率76.5%,其中肾阳虚型和肾阴虚型总有效率分别为97.2%和61.2%,急性再障(acute aplastic anemia,AAA)和慢性再障(chronic aplastic anemia,CAA)的总有效率分别为65.3%和91.7%,肾阳虚型AAA和CAA的有效率分别为100%和96.4%,肾阴虚型AAA和CAA的有效率分别为57.5%和75%,表明肾阳虚型疗效明显高于肾阴虚型,CAA疗效明显高于AAA患者,结果说明中西医分型原则的综合运用有助于预测AA的临床疗效。2.雄激素治疗有效病例以CAA20例(62.5%)、肾阳虚型21例(65.6%)为多;免疫抑制剂治疗有效病例以AAA16例(59.3%)、肾阴虚型17例(63%)为多。由以上可以大致看出,阳虚型和CAA较适宜于用雄激素治疗而AAA和阴虚型较适宜于用免疫抑制剂治疗,但判别准确率仅50%～60%。3.治疗前肾阴虚组外周血象(白细胞、血红蛋白、血小板)较。肾阳虚组低(P＜0.01),补肾中药治疗后肾阳虚组疗效(外周血象恢复)优于肾阴虚组(P＜0.01)。4.肾阴虚组治疗前症状较肾阳虚组重(P＜0.05),治疗后肾阳虚组疗效(症状减轻或消失)明显优于肾阴虚组(P＜0.05)。肾阴虚和肾阳虚组腰脊酸痛和胫酸膝软或足跟痛的频次都较多,说明腰脊酸痛和胫酸膝软或足跟痛是AA肾虚辨证主要症状。中医辨证肾阳虚型患者的临床症状轻,预后好;肾阴虚型患者临床表现重,预后相对较差。5.与对照组相比,治疗前AA患者出现一系列免疫指标变化,治疗后肾阳虚组各免疫指标与正常对照组比较已无差异,而肾阴虚组的免疫功能较肾阳虚组较难恢复;治疗后CAA各免疫指标与正常对照组比较已无差异,AAA的免疫功能较CAA更难恢复。6.分子生物学指标中,研究发现治疗前AA各组患者T-bet/β-actin和T-bet/GATA-3的对数明显低于健康对照组,经补肾中药治疗后恢复,GATA-3/β-actin的对数无显著变化。另从治疗效果分析,T-bet/β-actin的对数治疗前后在缓解组(疗效)都最高(P=0.033,P=0.017),T-bet/GATA-3的对数治疗前在缓解组(疗效)和免疫抑制剂组(治疗方法)最高(P=0.010,P=0.010),治疗后恢复正常;结果提示T-bet/GATA-3可能对雄激素和免疫抑制剂的使用具有预测作用。7.经过判别分析和回归分析,筛选出1g(T-bet/β-actin)、1g(T-bet/GATA-3)、Th1/Th2、CD3~+CD8~+(%)和CD3~+HLA-DR~+(%)共5项最有意义的指标做为预测指标,综合临床诊断标准,得出免疫抑制剂或雄激素选择用药的预测回归方程。8.按SPSS的ROC曲线模型,设定假阳性率为10%,取P值为0.832。若P值大于或等于0.832时,患者判定为免疫抑制为主状态,应以补肾中药加免疫抑制剂为主治疗;若P值小于0.832时,患者判定为骨髓衰竭为主状态,应以补肾中药加雄激素治疗。9.预测方程的临床可行性检验与评价说明,42.2%(14/33)的患者可能受益于预测结果而提高治疗效果。所以,预测方程可能提高临床治疗AA的治疗效率,协助临床医师进行合适的用药选择。
结论:1.中医辨证肾阳虚型AA临床症状明显轻于肾阴虚型,中医辨证肾阳虚型AA的临床疗效优于肾阴虚型;2.提出并证明再障的发病大致可分为以异常免疫为主和以骨髓衰竭为主2个阶段,前一阶段以免疫抑制剂+中药活血解毒补肾为主治疗;后一阶段应以雄激素+补肾中药为主治疗,之间可能存在过渡阶段;3.AA的免疫异常阶段以CD3~+CD8~+、CD3~+CD25~+、CD3~+HLA-DR~+、Th1/Th2等免疫学指标和T-bet、GATA-3等基因表达异常为主要特征;4.首次通过判别分析和回归分析建立以免疫学、分子生物学等现代指标和临床信息等多变量组成的预测系统,并确定以异常免疫为主和以骨髓衰竭为主2个阶段的分界点为P=0.832,以选择治疗策略。5.回顾性临床可行性检验显示预测系统的准确率为88.9%,有可能提高再障的临床疗效。
Purpose To do researches on T lymphocyte cell subgroups, T helper cells (Th), T-bet and GATA-3 gene expression regularity in aplastic anemia (AA) patients' peripheral blood. To evaluate the potential usefulness of a multivariable model in predicting the selection of immunosuppressive therapy (IST) or androgens in patients with AA, which coagulate immunology, microbiology and clinical parameters in all, and its application to the clinical practice.
Methods 85 patients were selected and treated in general. There were 4 forms of groups to be made according to symptoms of differenciation in traditional Chinese medicine (TCM), diagnosis in modern medicine, effectiveness and therapeutic methods. Peripheral blood T cell sub-groups and Th were serially analyzed by flow cytometer before and after the treatment. At the same time T-bet and GATA-3 genes were also assessed by real time RT-PCR. Then Logistic formulate and ROC curves were made based on cases responding to IST or Androgens. The multivariable model is set up to predict the selection of drugs (IST or Androgens) in clinical practice.
Results 1. After treatments for 2 courses, the total effectiveness ratio in kidney-yin deficiency group and kidney-yang deficiency group were respectively 97.2% and 61.2%. In acute aplastic anemia (AAA) and chronic aplastic anemia (CAA) groups they were 65.3% and 91.7% respectively, AAA and CAA in kidney-yang deficiency group were 100% and 96.4%, AAA and CAA in kidney-yin deficiency group were 57.5% and 75%. The above results showed that curative effect in kidney-yang group was higher than kidney-yin group, and CAA higher than AAA group, which administrated that Chinese and western cooperational dignostic methods were helpful to predict therapeutic effect. 2. The curative patients with androgens (62.5%) were more in CAA (62.5%) and kidney-yang deficiency group (65.6%). The therapeutic patients with IST were more in AAA (59.3%) and kidney-yin deficiency group (63%). So from the above data, we could conclude that CAA in kidney-yang deficiency group was better to use androgens and AAA in kidney-yin group was better with IST. However, the accurative ratio was 50%~60%. 3. The peripheral blood in kidney-yin deficiency group was much lower than kidney-yang deficiency group as white blood cell (WBC), hemoglobin (HB) and platelet (PUT) was discussed (P<0.01). And after treatment, the therapeutic effect in kidney-yang deficiency group was better (P<0.01).4. The symptoms in kidney-yin group were more serious than those of kidney-yang deficiency group (P<0.05). The symptoms in kidney-yang deficiency group dicreased and patients recover more obviously (P<0.05). In all the symptoms observed, lumbar ache and painful heel were more often seen and can be made main symptoms of kidney deficiency syndrome. As curation was concerned, kidney-yang deficiency group was more curable than kidney-yin deficiency group. 5. Compared with controls, before the treatment, there were a series of immunological factors differenciation in AA patients. They returned to normal and had no significent differences in kidney-yang deficiency group as with controls, though in kidney-yin group the immune function was not yet recovered and rather contractory. And in diagnostic groups, immunological terms in AAA were more difficult to ameliorate than those in CAA group. 6.The logarithm of T-bet/β-actin in Kidney-Yang group, chronic AA group, partly cured group decreased obviously (P<0.05). After Bushen Chinese herbs' treatment, The logarithm of T-bet/β-actin changed and lowered in kidney-yin deficiency group, acute AA group and partly cured group (P<0.05). The logarithm of T-bet/GATA-3 in kidney-yin deficiency group, chronic AA group, group of no respondence minimized statistically, which changed to normal level after Chinese herbs' treatment. The results inferred that T-bet/GATA-3 might have predictions of androgens and IST selections. 7.With the discriminant and logistic statistics, lg(T-bet/β-actin), lg(T-bet/GATA-3), Thl/Th2, CD3~+CD8~+(%) and CD3~+HLA-DR~+(%) 5 indexes were screened out to act as predicting factors. Together with clinical symptoms and diagnosis, the logistic formula was made to predict the selection of IST or androgen drugs. 8. A point between the 2 stages was found out through the calculation of the logistic formulate and ROC curve. The point was 0.832. When P≥0.832, it was in the abnormal immunological stage, IST should be used. When P<0.832, then it was in the bone marrow failure stage, androgens should be added. 9.The predictive formula indications of clinical probabilities and evaluations showed that 42.2%(14/33) patients could have benefits from the predictions made by the formula, which could advance the curative ratio and fanal results. All in all, the predictive system could obviously enhance AA curativeness and did well to clinical physicians in selection of androgens or IST properly and accurately.
Conclusions 1. Bushen Chinese herbs have effectiveness and accuracy of treating AA with no side effect. The therapeutic effect of Bushen Chinese herbs is more effeictive in kidney-yang group than in that in kidney-yin group. 2. A noval theory is proposed that there are 2 stages that are abnormal immunological stage and bone marrow failure stage in the course of AA. In the former stage, IST should be used. In the later one, androgens are prefered. 3. Immunologicl factors as CD3~+CD8~+, CD3~+CD25~+, CD3~+HLA-DR~+, Thl/Th2 and microbiological factors as T-bet and GATA-3 genes are the characteristics of abnormal state in AA patients. 4. A formula incorporating laboratory terms and clinical evidence is made to predict selections of IST and androgens. A point of P=0.832 is ascertained as the borderline of 2 states in AA, which are abmoral immunological state and bone marrow failure state. 5. Retrospective clinical probability analysis shows that the exactivity of the prodicting system is 88.9%, probably raising the effectiveness of AA.
方法:采用流式细胞术检测85例AA患者治疗前后外周血T细胞亚群及其他免疫学指标,同时运用实时监测定量PCR技术检测T-bet和GATA-3基因,从中医辨证(肾阳虚/肾阴虚)、西医诊断(急性再障/慢性再障)、疗效(缓解/进步/无效)和治疗方法(雄激素有效/无效和免疫抑制剂有效/无效)四个角度对AA患者进行不同分组,寻找表达显著的免疫学和分子生物学指标,筛选有临床意义并有显著差异性的指标,结合临床诊断依据,以雄激素和免疫抑制治疗有效病例做Logistic回归方程及ROC曲线分析,建立以临床和实验指标为主组成的预测系统,对临床治疗用药选择进行预测。
结果:1.总计85例AA患者经过两个疗程治疗,总有效率76.5%,其中肾阳虚型和肾阴虚型总有效率分别为97.2%和61.2%,急性再障(acute aplastic anemia,AAA)和慢性再障(chronic aplastic anemia,CAA)的总有效率分别为65.3%和91.7%,肾阳虚型AAA和CAA的有效率分别为100%和96.4%,肾阴虚型AAA和CAA的有效率分别为57.5%和75%,表明肾阳虚型疗效明显高于肾阴虚型,CAA疗效明显高于AAA患者,结果说明中西医分型原则的综合运用有助于预测AA的临床疗效。2.雄激素治疗有效病例以CAA20例(62.5%)、肾阳虚型21例(65.6%)为多;免疫抑制剂治疗有效病例以AAA16例(59.3%)、肾阴虚型17例(63%)为多。由以上可以大致看出,阳虚型和CAA较适宜于用雄激素治疗而AAA和阴虚型较适宜于用免疫抑制剂治疗,但判别准确率仅50%～60%。3.治疗前肾阴虚组外周血象(白细胞、血红蛋白、血小板)较。肾阳虚组低(P＜0.01),补肾中药治疗后肾阳虚组疗效(外周血象恢复)优于肾阴虚组(P＜0.01)。4.肾阴虚组治疗前症状较肾阳虚组重(P＜0.05),治疗后肾阳虚组疗效(症状减轻或消失)明显优于肾阴虚组(P＜0.05)。肾阴虚和肾阳虚组腰脊酸痛和胫酸膝软或足跟痛的频次都较多,说明腰脊酸痛和胫酸膝软或足跟痛是AA肾虚辨证主要症状。中医辨证肾阳虚型患者的临床症状轻,预后好;肾阴虚型患者临床表现重,预后相对较差。5.与对照组相比,治疗前AA患者出现一系列免疫指标变化,治疗后肾阳虚组各免疫指标与正常对照组比较已无差异,而肾阴虚组的免疫功能较肾阳虚组较难恢复;治疗后CAA各免疫指标与正常对照组比较已无差异,AAA的免疫功能较CAA更难恢复。6.分子生物学指标中,研究发现治疗前AA各组患者T-bet/β-actin和T-bet/GATA-3的对数明显低于健康对照组,经补肾中药治疗后恢复,GATA-3/β-actin的对数无显著变化。另从治疗效果分析,T-bet/β-actin的对数治疗前后在缓解组(疗效)都最高(P=0.033,P=0.017),T-bet/GATA-3的对数治疗前在缓解组(疗效)和免疫抑制剂组(治疗方法)最高(P=0.010,P=0.010),治疗后恢复正常;结果提示T-bet/GATA-3可能对雄激素和免疫抑制剂的使用具有预测作用。7.经过判别分析和回归分析,筛选出1g(T-bet/β-actin)、1g(T-bet/GATA-3)、Th1/Th2、CD3~+CD8~+(%)和CD3~+HLA-DR~+(%)共5项最有意义的指标做为预测指标,综合临床诊断标准,得出免疫抑制剂或雄激素选择用药的预测回归方程。8.按SPSS的ROC曲线模型,设定假阳性率为10%,取P值为0.832。若P值大于或等于0.832时,患者判定为免疫抑制为主状态,应以补肾中药加免疫抑制剂为主治疗;若P值小于0.832时,患者判定为骨髓衰竭为主状态,应以补肾中药加雄激素治疗。9.预测方程的临床可行性检验与评价说明,42.2%(14/33)的患者可能受益于预测结果而提高治疗效果。所以,预测方程可能提高临床治疗AA的治疗效率,协助临床医师进行合适的用药选择。
结论:1.中医辨证肾阳虚型AA临床症状明显轻于肾阴虚型,中医辨证肾阳虚型AA的临床疗效优于肾阴虚型;2.提出并证明再障的发病大致可分为以异常免疫为主和以骨髓衰竭为主2个阶段,前一阶段以免疫抑制剂+中药活血解毒补肾为主治疗;后一阶段应以雄激素+补肾中药为主治疗,之间可能存在过渡阶段;3.AA的免疫异常阶段以CD3~+CD8~+、CD3~+CD25~+、CD3~+HLA-DR~+、Th1/Th2等免疫学指标和T-bet、GATA-3等基因表达异常为主要特征;4.首次通过判别分析和回归分析建立以免疫学、分子生物学等现代指标和临床信息等多变量组成的预测系统,并确定以异常免疫为主和以骨髓衰竭为主2个阶段的分界点为P=0.832,以选择治疗策略。5.回顾性临床可行性检验显示预测系统的准确率为88.9%,有可能提高再障的临床疗效。
Purpose To do researches on T lymphocyte cell subgroups, T helper cells (Th), T-bet and GATA-3 gene expression regularity in aplastic anemia (AA) patients' peripheral blood. To evaluate the potential usefulness of a multivariable model in predicting the selection of immunosuppressive therapy (IST) or androgens in patients with AA, which coagulate immunology, microbiology and clinical parameters in all, and its application to the clinical practice.
Methods 85 patients were selected and treated in general. There were 4 forms of groups to be made according to symptoms of differenciation in traditional Chinese medicine (TCM), diagnosis in modern medicine, effectiveness and therapeutic methods. Peripheral blood T cell sub-groups and Th were serially analyzed by flow cytometer before and after the treatment. At the same time T-bet and GATA-3 genes were also assessed by real time RT-PCR. Then Logistic formulate and ROC curves were made based on cases responding to IST or Androgens. The multivariable model is set up to predict the selection of drugs (IST or Androgens) in clinical practice.
Results 1. After treatments for 2 courses, the total effectiveness ratio in kidney-yin deficiency group and kidney-yang deficiency group were respectively 97.2% and 61.2%. In acute aplastic anemia (AAA) and chronic aplastic anemia (CAA) groups they were 65.3% and 91.7% respectively, AAA and CAA in kidney-yang deficiency group were 100% and 96.4%, AAA and CAA in kidney-yin deficiency group were 57.5% and 75%. The above results showed that curative effect in kidney-yang group was higher than kidney-yin group, and CAA higher than AAA group, which administrated that Chinese and western cooperational dignostic methods were helpful to predict therapeutic effect. 2. The curative patients with androgens (62.5%) were more in CAA (62.5%) and kidney-yang deficiency group (65.6%). The therapeutic patients with IST were more in AAA (59.3%) and kidney-yin deficiency group (63%). So from the above data, we could conclude that CAA in kidney-yang deficiency group was better to use androgens and AAA in kidney-yin group was better with IST. However, the accurative ratio was 50%~60%. 3. The peripheral blood in kidney-yin deficiency group was much lower than kidney-yang deficiency group as white blood cell (WBC), hemoglobin (HB) and platelet (PUT) was discussed (P<0.01). And after treatment, the therapeutic effect in kidney-yang deficiency group was better (P<0.01).4. The symptoms in kidney-yin group were more serious than those of kidney-yang deficiency group (P<0.05). The symptoms in kidney-yang deficiency group dicreased and patients recover more obviously (P<0.05). In all the symptoms observed, lumbar ache and painful heel were more often seen and can be made main symptoms of kidney deficiency syndrome. As curation was concerned, kidney-yang deficiency group was more curable than kidney-yin deficiency group. 5. Compared with controls, before the treatment, there were a series of immunological factors differenciation in AA patients. They returned to normal and had no significent differences in kidney-yang deficiency group as with controls, though in kidney-yin group the immune function was not yet recovered and rather contractory. And in diagnostic groups, immunological terms in AAA were more difficult to ameliorate than those in CAA group. 6.The logarithm of T-bet/β-actin in Kidney-Yang group, chronic AA group, partly cured group decreased obviously (P<0.05). After Bushen Chinese herbs' treatment, The logarithm of T-bet/β-actin changed and lowered in kidney-yin deficiency group, acute AA group and partly cured group (P<0.05). The logarithm of T-bet/GATA-3 in kidney-yin deficiency group, chronic AA group, group of no respondence minimized statistically, which changed to normal level after Chinese herbs' treatment. The results inferred that T-bet/GATA-3 might have predictions of androgens and IST selections. 7.With the discriminant and logistic statistics, lg(T-bet/β-actin), lg(T-bet/GATA-3), Thl/Th2, CD3~+CD8~+(%) and CD3~+HLA-DR~+(%) 5 indexes were screened out to act as predicting factors. Together with clinical symptoms and diagnosis, the logistic formula was made to predict the selection of IST or androgen drugs. 8. A point between the 2 stages was found out through the calculation of the logistic formulate and ROC curve. The point was 0.832. When P≥0.832, it was in the abnormal immunological stage, IST should be used. When P<0.832, then it was in the bone marrow failure stage, androgens should be added. 9.The predictive formula indications of clinical probabilities and evaluations showed that 42.2%(14/33) patients could have benefits from the predictions made by the formula, which could advance the curative ratio and fanal results. All in all, the predictive system could obviously enhance AA curativeness and did well to clinical physicians in selection of androgens or IST properly and accurately.
Conclusions 1. Bushen Chinese herbs have effectiveness and accuracy of treating AA with no side effect. The therapeutic effect of Bushen Chinese herbs is more effeictive in kidney-yang group than in that in kidney-yin group. 2. A noval theory is proposed that there are 2 stages that are abnormal immunological stage and bone marrow failure stage in the course of AA. In the former stage, IST should be used. In the later one, androgens are prefered. 3. Immunologicl factors as CD3~+CD8~+, CD3~+CD25~+, CD3~+HLA-DR~+, Thl/Th2 and microbiological factors as T-bet and GATA-3 genes are the characteristics of abnormal state in AA patients. 4. A formula incorporating laboratory terms and clinical evidence is made to predict selections of IST and androgens. A point of P=0.832 is ascertained as the borderline of 2 states in AA, which are abmoral immunological state and bone marrow failure state. 5. Retrospective clinical probability analysis shows that the exactivity of the prodicting system is 88.9%, probably raising the effectiveness of AA.
引文
[1]张之南.血液病诊断及疗效标准.第2版.北京:北京科技出版社,1998.192.
[2]陈贵廷,杨思澍主编.实用中西医结合诊断治疗学.北京:中国医药科技出版社,1991.356.
[3]朱强.血复生为主治疗慢性再生障碍性贫血30例临床观察,江苏中医药,2005,26(8):16-17.
[4]周永明,黄振翘,黄韬,等.生血合剂治疗再生障碍性贫血的临床研究,中国中西医结合杂志,2000,20(3):173-175.
[5]曹道俊,黄霞,刘惠霞.熟地多糖补血作用的临床与实验研究,辽宁中医杂志,2005,32(12):1317-1318.
[6]曹红,胡宏.复方皂矾丸联合康尼龙治疗慢性再生障碍性贫血疗效观察,四川医学,2002,23(11):1151.
[7]戴微,陈志雄.补肾中药内外合治治疗慢性再生障碍性贫血的临床观察,广州中医药大学学报,2005,22(4):269-271.
[8]郭晓,张梅,张一昕,等.再障饮配合西药治疗再生障碍性贫血临床观察,中国中西医结合杂志,2003,23(10):730-731.
[9]纪春岩,王文,张茂宏.雄激素联合复方皂矾丸治疗再生障碍性贫血的疗效观察,山东大学学报(医学版),2002,40(5):25-30.
[10]刘瑜,于涛.中西医结合治疗慢性再生障碍性贫血46例疗效观察.现代中西医结合杂志,2005,14(10):1287.
[11]李晓惠,章亚成,陈建一,等.血复生汤为主治疗再生障碍性贫血118例的临床研究,江苏中医药,2002,23(12):10-11.
[12]罗耀光,刘燕群.益肾化瘀方配合小剂量雄激素治疗再生障碍性贫血的临床观察,中国中西医结合杂志,2000,20(6):459-460.
[13]马琳.升髓汤治疗再生障碍性贫血临床观察,四川中医,2001,19(4):51-52.
[14]邱仲川,赵琳,陈佩,等.补肾复方冲剂治疗肾阳虚型再生障碍性贫血.30例临床研究,中医杂志,2001,42(4):213-215.
[15]苏敬泽,张守琳.生髓活血胶囊对慢性再生障碍性贫血的临床及实验研究,中国中医基础医学杂志,2005,11(8):607-608.
[16]孙伟正,王祥麒,袁斌华,等.补髓生血胶囊治疗慢性再生障碍性贫血的临床观察,中国中西医 结合杂志,1997,17(8):467-469.
[17]孙伟正,邹长鹏,孙晓伟,等.补髓生血颗粒剂治疗慢性再生障碍性贫血的临床观察,中医药信息,2006,23(5):60-61.
[18]王树庆,唐迎雪,李建华,等.补肾活血通络法辅助治疗慢性再生障碍性贫血的临床研究,中国中西医结合杂志,2003,23(4):254-256.
[19]王树庆,刘捷,陈慧莉,等.补肾活血通络方治疗老年慢性再生障碍性贫血34例临床研究,中国老年学杂志,2007,27(2):339-340.
[20]魏学礼,周永明,袁乃荣,等.生血合剂治疗慢性再生障碍性贫血15例临床观察,江苏中医药,2006,27(9):46-47.
[21]夏小军,郭川,张鑫智,等.再障生血胶囊系列治疗慢性再生障碍性贫血临床观察,中国中医药信息杂志,2006,13(7):70-71.
[22]张蕾.补血合剂治疗慢性再生障碍性贫血的临床观察,辽宁中医杂志,2007,34(3):306-308.
[23]周霭祥,王天恩,杨经敏,等.益肾生血片为主治疗再生障碍性贫血的临床研究,中国中西医结合杂志.1998,18(10):603-605.
[1]Asnagli H,Murphy KM.The functional genomics experience(are you experienced?).Curr Opin Immunol,2001,2(9):826-828.
[2]Constant S,Bottomly K.Induction of Th1 and Th2 CD4+ T cell responses:the alternative approaches.Annu Rev lmmunol,1997,15:297-322.
[3]Agarwal S,Rao A.Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation.Immunity,1998,9(6):765-775.
[4]Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell,2000, 100(6): 655-669.
[5]Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Anna Rev Immunol, 1999,17:701-738.
[6]Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol, 1998,16:495-521.
[7] Wear KA, Garra BS. Assessment of bone density using ultrasonic backscatter. Ultrasound Med Biol, 1998,24(5):689-695.
[8]Iygo-Villarino G, Maldonado-Lopez R, Possemato R, et al. T-bet is required for optimal production of IFN-γ and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci USA, 2003, 100(13): 7749-7754.
[9] Wei H, Tian Z, Xu X, et al. Expression of transcription factor T-bet/GATA3 in lung cancer patients and its interference by the traditional Chinese herbal medicine. Zhonghua Zhong Liu Za Zhi,2002,24(1):34-37.
[10]Szabo SJ, Sullivan BAI, Stemmann C, et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T ells. Science, 2002, 295(5553): 338-342.
[11]Grogan JL, Mohrs M, Harmon B, et al. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immuity, 2001, 14(3): 205-215.
[12] White SJ, Underhill GH, Kaplan MH, et al. Cutting edge: differential requirements for Stat4 in expression of glycosyltransferases responsible for selectin ligand formation in Thl cells. J Immunol,2001,167(2):628-631.
[13]Lighvani AA, Fruncht DM, Jankovic D, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA, 2001, 98(26): 15137-15142.
[14]Eivazova ER, Anne TM. Dynamic alterations in the conformation of IFN-y gene region during T helper cell differentiation. Immunology, 2004,101(1): 251-256.
[15]Stnits HH, de Jong Ec, Schuitemaker JH, et al. Intercellular adhesion molecule-1/LFA-1 ligation favors human Thl development. J Immunol, 2002, 168(4): 1710-1716.
[16]Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up.genes Dev, 2000, 14(14): 1693-1711.
[17]Durali D, de Goer de Herve MG, GL-on-Michel J, et al. In human B cells, 11,12 triggers a cascade of molecular events similar to Thl commitment. Blood, 2003,102(12): 4084-4089.
[18]Gerth AJ, Lin L, Peng SL. T-bet regulates T-independent IgG2a class switching. Int Inmmnol, 2003, 15(8): 937-944.
[19] Liu N, Ohnishi N, Ni L, et al. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol, 2003,4(7): 687-693.
[20]Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science, 2001, 292(5523): 1907-1910.
[21] Yin Z, Chen C, Szabo SJ, et al. T-Bet expression and failure of GATA-3 cross-regulation lead to default production of IFN-gamma by gammadelta T cells. J Immunol, 2002, 168(4): 1566-1571.
[22] Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA, 2002, 99(8): 5545-5549.
[23]Chakir H, Wang H, Lefebvre DE, et al. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J immunol Methods, 2003,278(1-2):157-169.
[24]Melanitou E, Liu E, Miao D, et al. Absence of the T-bet gene coding for the Th1-related transcription factor does not affact diabetes-associated phenotypes in BA-/c mice. Ann N Y Acad Sci, 2003,1005:187-191.
[25]Neurath MF, Weignramn B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med, 2002, 195(9): 1129-1143.
[26]Weigmann B, Neurath MF. T-bet as a possible therapeutic target in autoimmune disease. Expert Opin Ther Targets, 2002,6(6): 619-622.
[27] Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science, 2002,295(5553): 336-338.
[28]Van Herpen CM, Huijbens R, Looman M, et al. Pharmacokinetics and immunological aspects of a phase 1b study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin Cancer Res, 2003,9(8): 2950-2956.
[29] Wagner HJ, Bollard CM, Vigouroux S, et al. A strategy for treatment of Epstein-Barr vL-us-positive Hodgkin's disease by targetting interleukin 12 to the tumor envL-onment using tumor antigen-specific T cells. Cancer Gene Ther, 2003,11(2): 81-91.
[30] Wei H, Sun R, Xiao W, et al. Traditional Chinese medicine Astragalus reverses predominance of Th2 cytokines and their up-stream transcript factors in lung cancer patients. Oncol Rep, 2003, 10(5): 1507-1512.
[31]Dorfman DM, van den Flzen P, Weng AP, et al. Differential expression of T-bet, a T-box transcrip-tion factor requL-ed for Th1 T-cell development, in peripheral T-cell lymphomas. Am J Clin Pathol, 2003, 120 (6): 866-873.
[32]Elena E Solomoul, Keyvan Keyvanfar, Neal S Young.T-bet, a Thl transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood, 2006,104(213): 876-286.
1.Maciejwski JP,Aderson S,Katevas,et al.Phenotypic and functional analysis of bone marrow progenitor cell component in bone marrow failure.Br J haematol,1994,87:227-230.
2.张之南,沈悌.血液病诊断及疗效标准.第三版.北京:科学出版社,2007.19-20.
3.沈自尹,王文健.中医虚证辨证参考标准.中西医结合杂志,1986,6(10):598.
4.刘润幸.使用SPSS作多变量观察值的ROC曲线分析.中国公共卫生,2003,19(9):1151-1152
5.Andrea Bacigalupo.Aplastic Anemia:Pathogenesis and Treatment.Hematology,2007(12):23-28.
6.Eva C.Guinan.Aplastic Anemia:Management of Pediatric Patients.Hematology,2005(12):104-109.
7.Judith Marsh.Making Therapeutic Decisions in Adults with Aplastic Anemia.Hematology,2006(12):79-85.
8.麻柔,周蔼祥,郑金福,等.慢性再生障碍性贫血患者患者外周血T淋巴细胞亚群改变与中医分型的关系.中国中西医结合杂志,1992,12(3):142-144.
9.周霭祥,王天恩,杨经敏,等.益肾生血片为主治疗再生障碍性贫血的临床研究.中国中西医结合杂志,1998,18(10):603-606.
10.丘仲川,赵琳,陈佩,等.补肾复方冲剂影响再生障碍性贫血患者造血祖细胞研究.北京中医药大学学报,2001,24(3):55-57.
11.周永明,黄振翘,黄韬,等.生血合剂治疗再生障碍性贫血的临床研究.中国中西医结合杂志,2000,20(3):173.
12.麻柔,谢仁敷,廖军鲜.成对和单味中药对造血细胞的作用.中西医结合杂志,1984,4(9):533-534.
13.陈忠,涂涛,方代南.南药巴戟天水提液对小鼠造血功能的影响研究初报.热带农业科学,2002,22(5):21-22,52.
14.李增喜.首乌制剂对血细胞的影响.中草药,1985,15(2):15.
15.丁雁,陈萍,刑善田,等.淫羊蕾多糖对叠氮胸若抑制小鼠造血和免疫功能的对抗作用.中国药理学与毒理学杂志,1994,8(3):203-205.
16.骆和生.中药方剂的药理与临床研究进展.广州:华南理工大学出版社,第1版, 1991.374.
17.Young NS,Maciejewski J.The pathophysiology of acquired aplastic anemia.N Engl J Med,1997,336:1365-1372.
18.Elena E Solomoul,Keyvan Keyvanfar,Neal S Young.T-bet,a Th1 transcription factor,is upregulated in T cells from patients with aplastic anemia.Blood,2006,107:
19.Mentzel U,Vogt H,et al Analysis of lymphocyte subsets in patients with aplastic anemia before and during immunosuppressive therapy.Ann Hematol 1993,66(3):127-129.
20.Ma Rou.Treatment of Bone Marrow Failure Syndromes with Integrated Traditional and Western Medicine.Chinese Janunal of Integrated Tranditional and Western Medicine,2007,13(3):85-89.
21.和虹,邵宗鸿,何广胜,等.Th1细胞在再生障碍性贫血发病机制中的作用.中华血液学杂志,2002,23(11):574-576.
22.Bacigalupo A,Podesta M,Mingari MC,et al,immune suppression of haematopoiesis in anlastic anemia activity of T Lymphocytes.J Immunol,1980,125:1449-1453.
23.李英梅,扬舟,郑以州.再生障碍性贫血造血干/祖细胞缺陷新认识.国际输血及血液学杂志,2008,3 1(1):25-29.
24.Maciejewski JP,Hibbs JR,Anderson S,et al.Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure.Exp Heamtol.1994,22:1102-1110.
25.Laver J,Castro,Kernan MA,etal.In vitro interferon-α production by cultured T cells in severe aplastic anemia:correlation with granulomonopoietic inhibition in patients who respond to anti thymocyte globulin.Br J Haematol,1988,69:545-550.
26.唐晓文.再生障碍性贫血患者外周血T细胞亚群测定.中华血液学杂志,1999,205-206.
27.傅晋翔,於葛华,张学光.再生障碍性贫血患者淋巴细胞表型变化.中华微生物学和免疫学杂志,2002,22(2):152-155.
28.夏长青.严重性再生障碍性贫血骨髓和外周血HLA-DR~+T细胞的变化及其淋巴细胞造血抑制活性的研究.中华血液学杂志,97(4):186-189.
29.Giarmakoulas NC,Karakantza M,Theodorou GL et al.Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients.Br J Haematol,2004,124:97-105.
30.Teramura M,Kobayashi S,Iwabe K et al.Mechanism of action of antithymocyte globulin in the treatment of aplastic anemia:in vitro evidence for the presence of immunosuppressive mechnism.Br J Haematol,1997,96:80-84.
31.Vale M,Merli A,Bacigalupo A.Analysis at the clonal level of T cell phenotype and functions in several aplastic anemia patiens.Blood,1991,78:1268.
32.MacDonald HR.Development and selection of NKT cells.Curr Opin Immunol,2002,14(2):250-254
33.Eivazova ER,Anne TM.Dynamic alterations in the conformation of IFN-γ gene region during T helper cell differentiation.Immunology,2004,101(1):251-256.
34.Smits HH,de Jong Ec,Schuitemaker JH,et al.J Immuno 1,2002,168:1710.
35.Solomou EE,Keyvanfar K,Young NS.T-bet,a Th1 transcrip-tion factor,is upregulated in T cells from patients with aplastic anemia.Blood,2006,107:3983-3991.
36.孙军,陈峰,郑凯尔.ROC曲线分析在放射学中的应用.中华放射学杂志,2001,35(8):574-577.
[2]陈贵廷,杨思澍主编.实用中西医结合诊断治疗学.北京:中国医药科技出版社,1991.356.
[3]朱强.血复生为主治疗慢性再生障碍性贫血30例临床观察,江苏中医药,2005,26(8):16-17.
[4]周永明,黄振翘,黄韬,等.生血合剂治疗再生障碍性贫血的临床研究,中国中西医结合杂志,2000,20(3):173-175.
[5]曹道俊,黄霞,刘惠霞.熟地多糖补血作用的临床与实验研究,辽宁中医杂志,2005,32(12):1317-1318.
[6]曹红,胡宏.复方皂矾丸联合康尼龙治疗慢性再生障碍性贫血疗效观察,四川医学,2002,23(11):1151.
[7]戴微,陈志雄.补肾中药内外合治治疗慢性再生障碍性贫血的临床观察,广州中医药大学学报,2005,22(4):269-271.
[8]郭晓,张梅,张一昕,等.再障饮配合西药治疗再生障碍性贫血临床观察,中国中西医结合杂志,2003,23(10):730-731.
[9]纪春岩,王文,张茂宏.雄激素联合复方皂矾丸治疗再生障碍性贫血的疗效观察,山东大学学报(医学版),2002,40(5):25-30.
[10]刘瑜,于涛.中西医结合治疗慢性再生障碍性贫血46例疗效观察.现代中西医结合杂志,2005,14(10):1287.
[11]李晓惠,章亚成,陈建一,等.血复生汤为主治疗再生障碍性贫血118例的临床研究,江苏中医药,2002,23(12):10-11.
[12]罗耀光,刘燕群.益肾化瘀方配合小剂量雄激素治疗再生障碍性贫血的临床观察,中国中西医结合杂志,2000,20(6):459-460.
[13]马琳.升髓汤治疗再生障碍性贫血临床观察,四川中医,2001,19(4):51-52.
[14]邱仲川,赵琳,陈佩,等.补肾复方冲剂治疗肾阳虚型再生障碍性贫血.30例临床研究,中医杂志,2001,42(4):213-215.
[15]苏敬泽,张守琳.生髓活血胶囊对慢性再生障碍性贫血的临床及实验研究,中国中医基础医学杂志,2005,11(8):607-608.
[16]孙伟正,王祥麒,袁斌华,等.补髓生血胶囊治疗慢性再生障碍性贫血的临床观察,中国中西医 结合杂志,1997,17(8):467-469.
[17]孙伟正,邹长鹏,孙晓伟,等.补髓生血颗粒剂治疗慢性再生障碍性贫血的临床观察,中医药信息,2006,23(5):60-61.
[18]王树庆,唐迎雪,李建华,等.补肾活血通络法辅助治疗慢性再生障碍性贫血的临床研究,中国中西医结合杂志,2003,23(4):254-256.
[19]王树庆,刘捷,陈慧莉,等.补肾活血通络方治疗老年慢性再生障碍性贫血34例临床研究,中国老年学杂志,2007,27(2):339-340.
[20]魏学礼,周永明,袁乃荣,等.生血合剂治疗慢性再生障碍性贫血15例临床观察,江苏中医药,2006,27(9):46-47.
[21]夏小军,郭川,张鑫智,等.再障生血胶囊系列治疗慢性再生障碍性贫血临床观察,中国中医药信息杂志,2006,13(7):70-71.
[22]张蕾.补血合剂治疗慢性再生障碍性贫血的临床观察,辽宁中医杂志,2007,34(3):306-308.
[23]周霭祥,王天恩,杨经敏,等.益肾生血片为主治疗再生障碍性贫血的临床研究,中国中西医结合杂志.1998,18(10):603-605.
[1]Asnagli H,Murphy KM.The functional genomics experience(are you experienced?).Curr Opin Immunol,2001,2(9):826-828.
[2]Constant S,Bottomly K.Induction of Th1 and Th2 CD4+ T cell responses:the alternative approaches.Annu Rev lmmunol,1997,15:297-322.
[3]Agarwal S,Rao A.Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation.Immunity,1998,9(6):765-775.
[4]Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell,2000, 100(6): 655-669.
[5]Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Anna Rev Immunol, 1999,17:701-738.
[6]Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol, 1998,16:495-521.
[7] Wear KA, Garra BS. Assessment of bone density using ultrasonic backscatter. Ultrasound Med Biol, 1998,24(5):689-695.
[8]Iygo-Villarino G, Maldonado-Lopez R, Possemato R, et al. T-bet is required for optimal production of IFN-γ and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci USA, 2003, 100(13): 7749-7754.
[9] Wei H, Tian Z, Xu X, et al. Expression of transcription factor T-bet/GATA3 in lung cancer patients and its interference by the traditional Chinese herbal medicine. Zhonghua Zhong Liu Za Zhi,2002,24(1):34-37.
[10]Szabo SJ, Sullivan BAI, Stemmann C, et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T ells. Science, 2002, 295(5553): 338-342.
[11]Grogan JL, Mohrs M, Harmon B, et al. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immuity, 2001, 14(3): 205-215.
[12] White SJ, Underhill GH, Kaplan MH, et al. Cutting edge: differential requirements for Stat4 in expression of glycosyltransferases responsible for selectin ligand formation in Thl cells. J Immunol,2001,167(2):628-631.
[13]Lighvani AA, Fruncht DM, Jankovic D, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA, 2001, 98(26): 15137-15142.
[14]Eivazova ER, Anne TM. Dynamic alterations in the conformation of IFN-y gene region during T helper cell differentiation. Immunology, 2004,101(1): 251-256.
[15]Stnits HH, de Jong Ec, Schuitemaker JH, et al. Intercellular adhesion molecule-1/LFA-1 ligation favors human Thl development. J Immunol, 2002, 168(4): 1710-1716.
[16]Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up.genes Dev, 2000, 14(14): 1693-1711.
[17]Durali D, de Goer de Herve MG, GL-on-Michel J, et al. In human B cells, 11,12 triggers a cascade of molecular events similar to Thl commitment. Blood, 2003,102(12): 4084-4089.
[18]Gerth AJ, Lin L, Peng SL. T-bet regulates T-independent IgG2a class switching. Int Inmmnol, 2003, 15(8): 937-944.
[19] Liu N, Ohnishi N, Ni L, et al. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol, 2003,4(7): 687-693.
[20]Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science, 2001, 292(5523): 1907-1910.
[21] Yin Z, Chen C, Szabo SJ, et al. T-Bet expression and failure of GATA-3 cross-regulation lead to default production of IFN-gamma by gammadelta T cells. J Immunol, 2002, 168(4): 1566-1571.
[22] Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA, 2002, 99(8): 5545-5549.
[23]Chakir H, Wang H, Lefebvre DE, et al. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J immunol Methods, 2003,278(1-2):157-169.
[24]Melanitou E, Liu E, Miao D, et al. Absence of the T-bet gene coding for the Th1-related transcription factor does not affact diabetes-associated phenotypes in BA-/c mice. Ann N Y Acad Sci, 2003,1005:187-191.
[25]Neurath MF, Weignramn B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med, 2002, 195(9): 1129-1143.
[26]Weigmann B, Neurath MF. T-bet as a possible therapeutic target in autoimmune disease. Expert Opin Ther Targets, 2002,6(6): 619-622.
[27] Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science, 2002,295(5553): 336-338.
[28]Van Herpen CM, Huijbens R, Looman M, et al. Pharmacokinetics and immunological aspects of a phase 1b study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin Cancer Res, 2003,9(8): 2950-2956.
[29] Wagner HJ, Bollard CM, Vigouroux S, et al. A strategy for treatment of Epstein-Barr vL-us-positive Hodgkin's disease by targetting interleukin 12 to the tumor envL-onment using tumor antigen-specific T cells. Cancer Gene Ther, 2003,11(2): 81-91.
[30] Wei H, Sun R, Xiao W, et al. Traditional Chinese medicine Astragalus reverses predominance of Th2 cytokines and their up-stream transcript factors in lung cancer patients. Oncol Rep, 2003, 10(5): 1507-1512.
[31]Dorfman DM, van den Flzen P, Weng AP, et al. Differential expression of T-bet, a T-box transcrip-tion factor requL-ed for Th1 T-cell development, in peripheral T-cell lymphomas. Am J Clin Pathol, 2003, 120 (6): 866-873.
[32]Elena E Solomoul, Keyvan Keyvanfar, Neal S Young.T-bet, a Thl transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood, 2006,104(213): 876-286.
1.Maciejwski JP,Aderson S,Katevas,et al.Phenotypic and functional analysis of bone marrow progenitor cell component in bone marrow failure.Br J haematol,1994,87:227-230.
2.张之南,沈悌.血液病诊断及疗效标准.第三版.北京:科学出版社,2007.19-20.
3.沈自尹,王文健.中医虚证辨证参考标准.中西医结合杂志,1986,6(10):598.
4.刘润幸.使用SPSS作多变量观察值的ROC曲线分析.中国公共卫生,2003,19(9):1151-1152
5.Andrea Bacigalupo.Aplastic Anemia:Pathogenesis and Treatment.Hematology,2007(12):23-28.
6.Eva C.Guinan.Aplastic Anemia:Management of Pediatric Patients.Hematology,2005(12):104-109.
7.Judith Marsh.Making Therapeutic Decisions in Adults with Aplastic Anemia.Hematology,2006(12):79-85.
8.麻柔,周蔼祥,郑金福,等.慢性再生障碍性贫血患者患者外周血T淋巴细胞亚群改变与中医分型的关系.中国中西医结合杂志,1992,12(3):142-144.
9.周霭祥,王天恩,杨经敏,等.益肾生血片为主治疗再生障碍性贫血的临床研究.中国中西医结合杂志,1998,18(10):603-606.
10.丘仲川,赵琳,陈佩,等.补肾复方冲剂影响再生障碍性贫血患者造血祖细胞研究.北京中医药大学学报,2001,24(3):55-57.
11.周永明,黄振翘,黄韬,等.生血合剂治疗再生障碍性贫血的临床研究.中国中西医结合杂志,2000,20(3):173.
12.麻柔,谢仁敷,廖军鲜.成对和单味中药对造血细胞的作用.中西医结合杂志,1984,4(9):533-534.
13.陈忠,涂涛,方代南.南药巴戟天水提液对小鼠造血功能的影响研究初报.热带农业科学,2002,22(5):21-22,52.
14.李增喜.首乌制剂对血细胞的影响.中草药,1985,15(2):15.
15.丁雁,陈萍,刑善田,等.淫羊蕾多糖对叠氮胸若抑制小鼠造血和免疫功能的对抗作用.中国药理学与毒理学杂志,1994,8(3):203-205.
16.骆和生.中药方剂的药理与临床研究进展.广州:华南理工大学出版社,第1版, 1991.374.
17.Young NS,Maciejewski J.The pathophysiology of acquired aplastic anemia.N Engl J Med,1997,336:1365-1372.
18.Elena E Solomoul,Keyvan Keyvanfar,Neal S Young.T-bet,a Th1 transcription factor,is upregulated in T cells from patients with aplastic anemia.Blood,2006,107:
19.Mentzel U,Vogt H,et al Analysis of lymphocyte subsets in patients with aplastic anemia before and during immunosuppressive therapy.Ann Hematol 1993,66(3):127-129.
20.Ma Rou.Treatment of Bone Marrow Failure Syndromes with Integrated Traditional and Western Medicine.Chinese Janunal of Integrated Tranditional and Western Medicine,2007,13(3):85-89.
21.和虹,邵宗鸿,何广胜,等.Th1细胞在再生障碍性贫血发病机制中的作用.中华血液学杂志,2002,23(11):574-576.
22.Bacigalupo A,Podesta M,Mingari MC,et al,immune suppression of haematopoiesis in anlastic anemia activity of T Lymphocytes.J Immunol,1980,125:1449-1453.
23.李英梅,扬舟,郑以州.再生障碍性贫血造血干/祖细胞缺陷新认识.国际输血及血液学杂志,2008,3 1(1):25-29.
24.Maciejewski JP,Hibbs JR,Anderson S,et al.Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure.Exp Heamtol.1994,22:1102-1110.
25.Laver J,Castro,Kernan MA,etal.In vitro interferon-α production by cultured T cells in severe aplastic anemia:correlation with granulomonopoietic inhibition in patients who respond to anti thymocyte globulin.Br J Haematol,1988,69:545-550.
26.唐晓文.再生障碍性贫血患者外周血T细胞亚群测定.中华血液学杂志,1999,205-206.
27.傅晋翔,於葛华,张学光.再生障碍性贫血患者淋巴细胞表型变化.中华微生物学和免疫学杂志,2002,22(2):152-155.
28.夏长青.严重性再生障碍性贫血骨髓和外周血HLA-DR~+T细胞的变化及其淋巴细胞造血抑制活性的研究.中华血液学杂志,97(4):186-189.
29.Giarmakoulas NC,Karakantza M,Theodorou GL et al.Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients.Br J Haematol,2004,124:97-105.
30.Teramura M,Kobayashi S,Iwabe K et al.Mechanism of action of antithymocyte globulin in the treatment of aplastic anemia:in vitro evidence for the presence of immunosuppressive mechnism.Br J Haematol,1997,96:80-84.
31.Vale M,Merli A,Bacigalupo A.Analysis at the clonal level of T cell phenotype and functions in several aplastic anemia patiens.Blood,1991,78:1268.
32.MacDonald HR.Development and selection of NKT cells.Curr Opin Immunol,2002,14(2):250-254
33.Eivazova ER,Anne TM.Dynamic alterations in the conformation of IFN-γ gene region during T helper cell differentiation.Immunology,2004,101(1):251-256.
34.Smits HH,de Jong Ec,Schuitemaker JH,et al.J Immuno 1,2002,168:1710.
35.Solomou EE,Keyvanfar K,Young NS.T-bet,a Th1 transcrip-tion factor,is upregulated in T cells from patients with aplastic anemia.Blood,2006,107:3983-3991.
36.孙军,陈峰,郑凯尔.ROC曲线分析在放射学中的应用.中华放射学杂志,2001,35(8):574-577.